Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript. A question was raised about promoters' pledged shares and recent fundraise, but no specific details on new fundraising plans were disclosed. The company discussed ongoing investments in marketing, new business expansions (e.g., Tanzania, Think Health), but funding sources were not detailed. ESOPs are in place as a talent retention mechanism, recorded as expenses but not cash outflows. Overall, the management focused on organic growth and strategic investments without indicating

Any current/future capex/capital investment/strategic investment?

Thyrocare is investing in geographic expansion, including a new venture in Tanzania, aiming to launch affordable diagnostic tests in that country. The company is scaling up Think Health, which provides ECG at home services, enhancing offerings especially for insurance partners. They continue investing in quality improvements, expanding reach, and improving turnaround time to maintain best-in-class service. Marketing and promotion costs of approximately Rs. 8-10 crores were spent in FY24, mainly to promote new packages and brand JAANCH. Investments are also being made in partnerships with hospi

Future growth expectations in sales/revenue/volumes?

FY25 growth guidance targets mid-teen revenue growth of 15%-18% (Alok Jagnani). Franchisee business expected to return to high teens growth rate post stabilization of small franchisee churn. Partnership business excluding API and B2G expected to continue strong growth, leveraging hospital and insurance segment expansions. Volume growth: Core franchise business grew 8% in FY24 (year-on-year) with 10% quarter-on-quarter sample growth. Focus on geographic expansion deeper into India, enhanced service offerings (e.g., ECG at home via Think Health acquisition). Marketing investments continue to pro

Future growth expectations in earnings/operating earnings/profits/EPS?

FY25 growth strategy focuses on expanding core franchise business by deepening penetration in new cities and geographies. Increased focus on partnership business, especially targeting large hospital accounts and insurance sectors, enhanced by ECG capabilities through Think Health acquisition. Revenue growth guidance for FY25: mid-teen growth expected (15%-18%), improving from FY24's 9% growth. Franchisee business expected to return to high teens growth, driven by stabilization and growth in large franchisees. Normalized EBITDA margins expected to be stable around 28%-29%; reported EBITDA margi

Thyrocare Technologies LtdQ4 FY24Healthcare Services

Thyrocare Technologies Ltd Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹534P/E: 49.9Market Cap: ₹9.0K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

FY25 growth guidance targets mid-teen revenue growth of 15%-18% (Alok Jagnani).
Franchisee business expected to return to high teens growth rate post stabilization of small franchisee churn.
Partnership business excluding API and B2G expected to continue strong growth, leveraging hospital and insurance segment expansions.
Volume growth: Core franchise business grew 8% in FY24 (year-on-year) with 10% quarter-on-quarter sample growth.
Focus on geographic expansion deeper into India, enhanced service offerings (e.g., ECG at home via Think Health acquisition).
Marketing investments continue to promote new packages like JAANCH and Her Check driving brand growth.
New international market entry: Tanzania launch anticipated to open significant affordable testing opportunities.
Expect revenue growth driven by a mix shift towards larger franchisees and strategic partnerships, not just price increases.
Promotion costs and new initiatives investment to sustain growth momentum.

Margin guidance

Category 3

FY25 growth strategy focuses on expanding core franchise business by deepening penetration in new cities and geographies.
Increased focus on partnership business, especially targeting large hospital accounts and insurance sectors, enhanced by ECG capabilities through Think Health acquisition.
Revenue growth guidance for FY25: mid-teen growth expected (15%-18%), improving from FY24's 9% growth.
Franchisee business expected to return to high teens growth, driven by stabilization and growth in large franchisees.
Normalized EBITDA margins expected to be stable around 28%-29%; reported EBITDA margins may improve as ESOP charges reduce.
Margins to remain flat due to ongoing investments in Tanzania, Think Health, and other expansion efforts.
Marketing and business promotion spends for FY25 will remain at current levels with no major incremental spend.
Overall, the company anticipates steady earnings and operating profit growth supported by increased volume, deeper market penetration, and strategic partnerships.

See what Thyrocare Technologies Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript.
A question was raised about promoters' pledged shares and recent fundraise, but no specific details on new fundraising plans were disclosed.
The company discussed ongoing investments in marketing, new business expansions (e.g., Tanzania, Think Health), but funding sources were not detailed.
ESOPs are in place as a talent retention mechanism, recorded as expenses but not cash outflows.
Overall, the management focused on organic growth and strategic investments without indicating plans for fresh debt or equity issuance.

Order book

The transcript does not explicitly mention current or expected orderbook or pending orders details. However, relevant insights related to business outlook and growth include: - Focus on expanding franchise business deeper into India and strengthening core franchise and partnership models. - Emphasis on growing large franchisees, which contribute 90% of franchise revenue. - Partnership business excluding B2G and API showed strong growth (23% for the year, 40% in Q4). - New initiatives include expansion in Tanzania and scaling up Think Health (ECG at Home). - Government business focus shifted to niche areas like TB and infectious diseases with screening partnerships. - Marketing spends (Rs. 8-10 crores for FY24) targeted promotional projects like JAANCH and Hitech branding to bolster growth. - No specific numeric order backlog or pending orders disclosed in the call.

See what Thyrocare Technologies Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Thyrocare is investing in geographic expansion, including a new venture in Tanzania, aiming to launch affordable diagnostic tests in that country.
The company is scaling up Think Health, which provides ECG at home services, enhancing offerings especially for insurance partners.
They continue investing in quality improvements, expanding reach, and improving turnaround time to maintain best-in-class service.
Marketing and promotion costs of approximately Rs. 8-10 crores were spent in FY24, mainly to promote new packages and brand JAANCH.
Investments are also being made in partnerships with hospitals and insurance sectors to drive growth.
Capex in new initiatives like Tanzania and Think Health may initially impact margins but are expected to deliver long-term operating leverage.
No specific detailed capital expenditure amounts disclosed beyond marketing spends and startup costs for new initiatives.

Track Thyrocare Technologies Ltd — get its next earnings analysis in your feed

How does Thyrocare Technologies Ltd rank vs peers in Healthcare Services?

Pro feature

ThisThyrocare Technologies Ltd

Rev 3Mar 3

See where Thyrocare Technologies Ltd sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Thyrocare Technologies Ltd rank in Healthcare Services?

Compare Thyrocare Technologies Ltd against every Healthcare Services company (Q4 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Thyrocare Technologies Ltd's management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Thyrocare Technologies Ltd Q4 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Thyrocare Technologies Ltd rank in Healthcare Services?

Continue your research

What Thyrocare Technologies Ltd's management said in earlier quarters

Others in Healthcare Services this season